Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
1.065
+0.015 (1.43%)
Sep 16, 2025, 2:55 PM EDT - Market open
Outlook Therapeutics Employees
Outlook Therapeutics had 23 employees as of September 30, 2024. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
$65,449
Profits / Employee
-$1,888,731
Market Cap
47.31M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 23 | -1 | -4.17% |
Sep 30, 2023 | 24 | 7 | 41.18% |
Sep 30, 2022 | 17 | 8 | 88.89% |
Sep 30, 2021 | 9 | 1 | 12.50% |
Sep 30, 2020 | 8 | -6 | -42.86% |
Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OTLK News
- 13 days ago - Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS) - GlobeNewsWire
- 14 days ago - Outlook Therapeutics Requests Type A Meeting with FDA - GlobeNewsWire
- 19 days ago - Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug - Invezz
- 19 days ago - FDA Rejects Outlook Therapeutics Eye Drug For Second Time - Benzinga
- 19 days ago - US FDA declines to approve Outlook Therapeutics' drug for eye condition - Reuters
- 19 days ago - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD - GlobeNewsWire
- 23 days ago - Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision - Seeking Alpha
- 4 weeks ago - Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire